Results for this period
Third quarter1 January 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Net sales increased, led by direct sales, and new urology products performed well. Meanwhile, the cost of sales ratio rose due to the weaker yen and other factors, while selling, general and administrative expenses increased due to higher costs associated with strengthening the overseas business and M&A.
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 September 2026 |
| Net Sales | ¥10,467 million (YoY +4.1%) |
| Operating profit | ¥509 million (YoY -44.2%) |
| Ordinary income | ¥568 million (YoY -34.8%) |
| Profit attributable to owners of the parent | ¥301 million (YoY -54.7%) |
| Net income per share | ¥37.05 |
| Equity ratio | End of the current fiscal period 81.4 / End of previous period 81.1 |
| Total assets | ¥19,831 million |
| Net assets | ¥16,148 million |
| Full-year earnings forecast | Net Sales ¥13,960 million (YoY +2.5%) / Operating profit ¥760 million (YoY -24.4%) / Ordinary income ¥800 million (YoY -19.0%) / Net income ¥560 million (YoY -21.5%) |
| Annual Dividend Forecast | ¥45 → ¥47（+4.4%） |
| Depreciation and amortization | ¥467,351 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Government grants / Amount ¥2,113 thousand / Extraordinary loss No |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable None / Subject person Not disclosed |
| Issued Shares at Period-End | 9,664,327 |
| Treasury Shares at Period-End | 1,704,726 |
| Factors Behind Changes in Business Performance | Net sales increased, led by direct sales, and new urology products performed well. Meanwhile, the cost of sales ratio rose due to the weaker yen and other factors, while selling, general and administrative expenses increased due to higher costs associated with strengthening the overseas business and M&A. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Selling, general and administrative expenses increased due to the rise in the cost of sales ratio resulting from the weaker yen and other factors, as well as higher costs associated with strengthening the overseas business and M&A. Net sales increased, led by direct sales, with new urology products performing particularly well.